Risedronate Sodium Tablet, Delayed Release
Product Images NDC 63304-440

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 63304-440). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industires Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Fig1)

A bar chart comparing the percentage of patients experiencing events across various body sites between placebo and ACTONEL 5 mg groups. The chart displays data for all sites combined, waist, humerus, hip, pelvis, leg, and clavicle, with the placebo group represented by white bars and ACTONEL 5 mg group by black bars.*

FDA Label Image

Structure 01 (Image 02)

Chemical structure diagram of risedronate sodium, showing its molecular components including a pyridine ring, phosphate groups, and sodium ion as part of the compound.*

FDA Label Image

Spl Risedronate Carton

Packaging label for Risedronate Sodium Delayed-Release Tablets 35 mg by Sun Pharmaceutical Industries Inc. The label shows product name, strength, dosage form, and instructions to dispense the enclosed Medication Guide. It includes storage instructions and multiple barcodes. The package is designed for oral use with a prescription.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.